본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

Endocrine-related cancer 9건

  1. [해외논문]   Thyroid nodules and cancer management guidelines: comparisons and controversies   SCI SCIE

    Nabhan, Fadi (Division of Endocrinology, Diabetes and Metabolism, The Ohio State University College of Medicine, Wexner Medical Center, Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA ) , Ringel, Matthew D (Division of Endocrinology, Diabetes and Metabolism, The Ohio State University College of Medicine, Wexner Medical Center, Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA)
    Endocrine-related cancer v.24 no.2 ,pp. R13 - R26 , 2017 , 1351-0088 ,

    초록

    Thyroid cancer is an increasingly prevalent malignancy throughout the world. Management guidelines for both thyroid nodules and thyroid cancer have been published and updated by a number of societies internationally. All of these guidelines recognize this increasing incidence, particularly of small papillary thyroid cancers, due in part to improved technology enabling early or even ‘over’ diagnosis. Recent advances in molecular imaging and molecular methods have been developed to better characterize thyroid nodules, and a number of studies that have clarified risk stratification systems that can be modified over time allow for individualization of diagnosis, initial treatment, and subsequent follow-up strategies. Advances in surgical approaches and new treatments for patients with the most aggressive forms of thyroid cancer have all influenced management guidelines. Despite substantial similarities, there also are important differences between recent guidelines for some of the common clinical scenarios encountered by physicians in clinical practice. In the present manuscript, we will highlight similarities and differences between several of the most recently published guidelines focused on key areas of importance to clinical care and controversy. These are key areas for future research to strengthen the data to support future guideline recommendations.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [해외논문]   Regression of advanced neuroendocrine tumors among patients receiving placebo   SCI SCIE

    Amoroso, Vito (Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili, Brescia, Italy ) , Agazzi, Giorgio Maria (Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Radiology Unit, University of Brescia at ASST Spedali Civili, Brescia, Italy ) , Roca, Elisa (Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology Unit, University of Brescia at ASST Spedali Civili, Brescia, Italy ) , Fazio, Nicola (Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy ) , Mosca, Alessandra (Medical Oncology Unit, Maggiore della Carità) , Ravanelli, Marco (University Hospital, University of Eastern Piedmont, Novara, Italy ) , Spada, Francesca (Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Radiology Unit, University of Brescia at ASST Spedali Civili, Brescia, Italy ) , Maroldi, Roberto (Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, Euro) , Berruti, Alfredo
    Endocrine-related cancer v.24 no.2 ,pp. L13 - L16 , 2017 , 1351-0088 ,

    초록

    Thyroid cancer is an increasingly prevalent malignancy throughout the world. Management guidelines for both thyroid nodules and thyroid cancer have been published and updated by a number of societies internationally. All of these guidelines recognize this increasing incidence, particularly of small papillary thyroid cancers, due in part to improved technology enabling early or even ‘over’ diagnosis. Recent advances in molecular imaging and molecular methods have been developed to better characterize thyroid nodules, and a number of studies that have clarified risk stratification systems that can be modified over time allow for individualization of diagnosis, initial treatment, and subsequent follow-up strategies. Advances in surgical approaches and new treatments for patients with the most aggressive forms of thyroid cancer have all influenced management guidelines. Despite substantial similarities, there also are important differences between recent guidelines for some of the common clinical scenarios encountered by physicians in clinical practice. In the present manuscript, we will highlight similarities and differences between several of the most recently published guidelines focused on key areas of importance to clinical care and controversy. These are key areas for future research to strengthen the data to support future guideline recommendations.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [해외논문]   Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma   SCI SCIE

    Bahougne, Thibault (Service d'Endocrinologie et Diabétologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France ) , Imperiale, Alessio (Service de Biophysique et de Médecine Nucléaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France ) , Averous, Gerlinde (Département de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France ) , Chabrier, Gerard (Service d'Endocrinologie et Diabétologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France ) , Burnichon, Nelly (Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France ) , Gimenez-Roqueplo, Anne Paule (Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France ) , Dali-Youcef, Nassim (Laboratoire de Biochimie et de Biologie Moléculaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France ) , Libe, Rossella (Centre Expert National COMETE-Cancer de la surrénale, Paris, France ) , Baudin, Eric (Département de) , Roy, Catherine , Lang, Herve , Kessler, Laurence
    Endocrine-related cancer v.24 no.2 ,pp. L7 - L11 , 2017 , 1351-0088 ,

    초록

    Thyroid cancer is an increasingly prevalent malignancy throughout the world. Management guidelines for both thyroid nodules and thyroid cancer have been published and updated by a number of societies internationally. All of these guidelines recognize this increasing incidence, particularly of small papillary thyroid cancers, due in part to improved technology enabling early or even ‘over’ diagnosis. Recent advances in molecular imaging and molecular methods have been developed to better characterize thyroid nodules, and a number of studies that have clarified risk stratification systems that can be modified over time allow for individualization of diagnosis, initial treatment, and subsequent follow-up strategies. Advances in surgical approaches and new treatments for patients with the most aggressive forms of thyroid cancer have all influenced management guidelines. Despite substantial similarities, there also are important differences between recent guidelines for some of the common clinical scenarios encountered by physicians in clinical practice. In the present manuscript, we will highlight similarities and differences between several of the most recently published guidelines focused on key areas of importance to clinical care and controversy. These are key areas for future research to strengthen the data to support future guideline recommendations.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [해외논문]   Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism   SCI SCIE

    Beckers, Albert (Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium ) , Fernandes, Daniel (School of Archaeology and Earth Institute, University College Dublin, Belfield, Dublin, Ireland ) , Fina, Frederic (Assistance Publique Hôpitaux de Marseille (AP-HM) Hôpital Nord, Service de Transfert d'Oncologie Biologique, and Laboratoire de Biologie Médicale, and Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France ) , Novak, Mario (School of Archaeology and Earth Institute, University College Dublin, Belfield, Dublin, Ireland ) , Abati, Angelo (Department of Legal Medicine, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium ) , Rostomyan, Liliya (Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, Belgium ) , Thiry, Albert (Department of Pathology, Centre Hospitalier Uni) , Ouafik, L'Housine , Pasture, Bertrand , Pinhasi, Ron , Daly, Adrian F
    Endocrine-related cancer v.24 no.2 ,pp. L17 - L20 , 2017 , 1351-0088 ,

    초록

    Thyroid cancer is an increasingly prevalent malignancy throughout the world. Management guidelines for both thyroid nodules and thyroid cancer have been published and updated by a number of societies internationally. All of these guidelines recognize this increasing incidence, particularly of small papillary thyroid cancers, due in part to improved technology enabling early or even ‘over’ diagnosis. Recent advances in molecular imaging and molecular methods have been developed to better characterize thyroid nodules, and a number of studies that have clarified risk stratification systems that can be modified over time allow for individualization of diagnosis, initial treatment, and subsequent follow-up strategies. Advances in surgical approaches and new treatments for patients with the most aggressive forms of thyroid cancer have all influenced management guidelines. Despite substantial similarities, there also are important differences between recent guidelines for some of the common clinical scenarios encountered by physicians in clinical practice. In the present manuscript, we will highlight similarities and differences between several of the most recently published guidelines focused on key areas of importance to clinical care and controversy. These are key areas for future research to strengthen the data to support future guideline recommendations.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [해외논문]   Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases   SCI SCIE

    Karpathakis, Anna (University College London, London, UK ) , Dibra, Harpreet (University College London, London, UK ) , Pipinikas, Christodoulos (University College London, London, UK ) , Feber, Andrew (University College London, London, UK ) , Morris, Tiffany (University College London, London, UK ) , Francis, Joshua (The Broad Institute, Boston, Massachusetts, USA ) , Oukrif, Dahmane (University College London, London, UK ) , Mandair, Dalvinder (University College London, London, UK ) , Pericleous, Marinos (2The Royal Free Hospital, London, UK ) , Mohmaduvesh, Mullan (2The Royal Free Hospital, London, UK ) , Serra, Stefano (UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada ) , Ogunbiyi, Olagunju (The Broad Institute, Boston, Massachusetts, USA ) , Novelli, Marco (University College London, London, UK ) , Luong, TuVinh (2The Royal Free Hospital, London, UK ) , Asa, Sylvia L (UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada ) , Kulke, Matthew (DanaFaber Cancer Institute, Boston, Massachusetts, USA ) , Toumpanakis, Christos (2The Royal Free Hospital, London, UK ) , Meyer, Tim (University College London, London, UK ) , Caplin, Martyn (2The Royal Free Hospital, London, UK ) , Beck, Stephan (University College London, London, UK ) , Thirlwell, Christina (University College London, London, UK)
    Endocrine-related cancer v.24 no.2 ,pp. L21 - L25 , 2017 , 1351-0088 ,

    초록

    Thyroid cancer is an increasingly prevalent malignancy throughout the world. Management guidelines for both thyroid nodules and thyroid cancer have been published and updated by a number of societies internationally. All of these guidelines recognize this increasing incidence, particularly of small papillary thyroid cancers, due in part to improved technology enabling early or even ‘over’ diagnosis. Recent advances in molecular imaging and molecular methods have been developed to better characterize thyroid nodules, and a number of studies that have clarified risk stratification systems that can be modified over time allow for individualization of diagnosis, initial treatment, and subsequent follow-up strategies. Advances in surgical approaches and new treatments for patients with the most aggressive forms of thyroid cancer have all influenced management guidelines. Despite substantial similarities, there also are important differences between recent guidelines for some of the common clinical scenarios encountered by physicians in clinical practice. In the present manuscript, we will highlight similarities and differences between several of the most recently published guidelines focused on key areas of importance to clinical care and controversy. These are key areas for future research to strengthen the data to support future guideline recommendations.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [해외논문]   Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines   SCI SCIE

    Foulfoin, Margaux (Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France ) , Graillot, Emmanuelle (Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France ) , Adham, Mustapha (University of Lyon, Université) , Rousset, Pascal (Lyon 1, Lyon, France ) , Forestier, Julien (University of Lyon, Université) , Hervieu, Valé (Lyon 1, Lyon, France ) , rie (Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de Gastroentérologie et d'Oncologie Médicale, Lyon, France ) , Robinson, Philip (University of Lyon, Université) , Scoazec, Jean-Yves (Lyon 1, Lyon, France ) , Lombard-Bohas, Catherine (Hospices Civils de Lyon, DRCI, Lyon, France ) , Walter, Thomas (Hospices Civils de Lyon, Hôpital Edouard Herriot, Service Central d'Anatomie et Cytologie Pathologiques, Lyon, France )
    Endocrine-related cancer v.24 no.2 ,pp. 71 - 81 , 2017 , 1351-0088 ,

    초록

    The choice of first-line treatment for metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines stratified treatment according to 3 groups: Group 1, patients in whom all lesions could be removed; Group 2, patients with Ki67 <10%, low tumor burden, no symptoms and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group 3, symptomatic patients or with Ki67 >10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed. This retrospective study aimed to determine patient distribution, characteristics and outcome among these 3 groups. Patients with mP-NET diagnosis from 2004 to 2016 were categorized into the three groups. Prognosis was calculated using the Kaplan–Meier method. All treatments were recorded, and consistency with ENETS guidelines was explored. 104 patients were analyzed: 64% synchronous mP-NET, 80% grade 2 tumors and median overall survival (OS) of 104 (95% CI: 65–143) months. There were 15 patients in ENETS Group 1, 16 in Group 2 and 73 in Group 3. Median OS was not reached in Groups 1 and 2 and was 64 months (35–93) in Group 3. High liver tumor volume, high-grade tumor and progressive disease were associated with worse OS in multivariate analysis. The first-line treatment was in accordance with guidelines in 82%. 77% percent of deceased patients received less than 4 lines of treatment. Most patients are in Group 3 and do not receive all available treatments. Thus, trials are warranted to improve first-line chemotherapy. Alternative treatments may be considered for less aggressive disease.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [해외논문]   Bisphenol A and its analogues disrupt centrosome cycle and microtubule dynamics in prostate cancer   SCI SCIE

    Ho, Shuk-Mei (Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, Ohio, USA ) , Rao, Rahul (Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, Ohio, USA ) , To, Sarah (Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, Ohio, USA ) , Schoch, Emma (Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, Ohio, USA ) , Tarapore, Pheruza (Department of Environmental Health, University of Cincinnati Medical Center, Cincinnati, Ohio, USA)
    Endocrine-related cancer v.24 no.2 ,pp. 83 - 96 , 2017 , 1351-0088 ,

    초록

    Humans are increasingly exposed to structural analogues of bisphenol A (BPA), as BPA is being replaced by these compounds in BPA-free consumer products. We have previously shown that chronic and developmental exposure to BPA is associated with increased prostate cancer (PCa) risk in human and animal models. Here, we examine whether exposure of PCa cells (LNCaP, C4-2) to low-dose BPA and its structural analogues (BPS, BPF, BPAF, TBBPA, DMBPA and TMBPA) affects centrosome amplification (CA), a hallmark of cancer initiation and progression. We found that exposure to BPA, BPS, DMBPA and TBBPA, in descending order, increased the number of cells with CA, in a non-monotonic dose–response manner. Furthermore, cells treated with BPA and their analogues initiated centrosome duplication at 8 h after release from serum starvation, significantly earlier in G-1 phase than control cells. This response was attended by earlier release of nucleophosmin from unduplicated centrosomes. BPA-exposed cells exhibited increased expression of cyclin-dependent kinase CDK6 and decreased expression of CDK inhibitors ( p21 Waf1/CIP1 and p27 KIP1 ). Using specific antagonists for estrogen/androgen receptors, CA in the presence of BPA or its analogues was likely to be mediated via ESR1 signaling. Change in microtubule dynamics was observed on exposure to these analogues, which, for BPA, was accompanied by increased expression of centrosome-associated protein CEP350 . Similar to BPA, chronic treatment of cells with DMBPA, but not other analogues, resulted in the enhancement of anchorage-independent growth. We thus conclude that selected BPA analogues, similar to BPA, disrupt centrosome function and microtubule organization, with DMBPA displaying the broadest spectrum of cancer-promoting effects.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [해외논문]   Comprehensive screening for PD-L1 expression in thyroid cancer   SCI SCIE

    Ahn, Soomin (Department of Pathology, Ewha Womans University School of Medicine, Seoul, Korea ) , Kim, Tae Hyuk (Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea ) , Kim, Sun Wook (Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea ) , Ki, Chang Seok (Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea ) , Jang, Hye Won (Department of Medical Education, Sungkyunkwan University School of Medicine, Seoul, Korea ) , Kim, Jee Soo (Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea ) , Kim, Jung Han (Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea ) , Choe, Jun-Ho (Division of Breast and Endocrine Surgery, Department of Surgery, Sam) , Shin, Jung Hee , Hahn, Soo Yeon , Oh, Young Lyun , Chung, Jae Hoon
    Endocrine-related cancer v.24 no.2 ,pp. 97 - 106 , 2017 , 1351-0088 ,

    초록

    PD-L1 expression is being considered a potential biomarker for response of anti-PD-1 or anti-PD-L1 agents in various tumors. The reported frequency of PD-L1 positivity varies in thyroid carcinomas, and multiple factors may contribute to the variability in PD-L1 positivity. We evaluated the PD-L1 expression in various thyroid cancers on a large scale. A total of 407 primary thyroid cancers with a median 13.7-year of follow-up were included. We evaluated the frequency of PD-L1 expression using a rabbit monoclonal antibody (clone SP142). In addition, we analyzed the relationships between PD-L1 expression and clinicopathologic factors, including TERT promoter, BRAF status and disease progression. Tumoral PD-L1 was expressed in 6.1% of papillary thyroid carcinomas, 7.6% of follicular thyroid carcinomas and 22.2% of anaplastic thyroid carcinomas. The distribution of PD-L1 positivity was different according to cancer histology types (P

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [해외논문]   Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma   SCI SCIE

    Morandi, Luca (Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology 'M. Malpighi' at Bellaria Hospital, University of Bologna, Bologna, Italy ) , Righi, Alberto (Department of Pathology, Rizzoli Institute, (IRCCS), Bologna, Italy ) , Maletta, Francesca (Department of Medical Sciences, University of Turin, Turin, Italy ) , Rucci, Paola (Section of Hygiene and Biostatistics, University of Bologna, Bologna, Italy ) , Pagni, Fabio (Department of Pathology, University of Milano Bicocca, Monza, Italy ) , Gallo, Marco (Oncological Endocrinology Unit, Department of Medical Sciences, AOU Città) , Rossi, Sabrina (della Salute e della Scienza di Torino, University of Turin, Turin, Italy ) , Caporali, Leonardo (Department of Pathology, Regional Hospital, Treviso, Italy ) , Sapino, Anna (Istituto delle Scienze Neurologiche di Bologna (IRCCS), Bellaria Hospital, Bologna, Italy ) , Lloyd, Ricardo V (Institute for Cancer Research and Treatment (IRCCS), Candiolo, Italy ) , Asioli, Sofia (University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA )
    Endocrine-related cancer v.24 no.2 ,pp. 107 - 117 , 2017 , 1351-0088 ,

    초록

    Hobnail variant of papillary thyroid carcinoma (HPTC) represents a recently described, aggressive and rare group of thyroid tumors with poorly understood pathogenesis. Molecular data about this group of cancers are few, and a more detailed molecular characterization of these tumors is needed. The main objective of the study is to define a comprehensive molecular typing of HPTC. Eighteen patients affected by HPTC, including eighteen primary tumors and four lymph node metastases, were screened for NRAS , KRAS , HRAS , BRAF , TP53 , PIK3CA , hTERT , PTEN , CDKN2A , EGFR , AKT1 , CTNNB1 and NOTCH1 gene mutations. Sequencing is conducted on the MiSEQ system, and molecular data are compared with clinical-pathologic data and follow-up. The patients include 14 women and 4 men. Ages range from 23 to 87 years. All 18 primary tumors of HPTC showed ≥30% hobnail features. BRAF and TP53 mutations are by far the most common genetic alterations in primary HPTC (72.2% and 55.6%, respectively), followed by hTERT (44.4%), PIK3CA (27.8%), CTNNB1 (16.7%), EGFR (11.1%), AKT1 (5.5%) and NOTCH1 (5.5%). The mutational pattern in primary tumors and metastasis was usually maintained. Univariate Cox regression analyses with bootstrap procedure indicated a significantly increased mortality risk in patients harboring BRAF mutation and BRAF mutation associated with TP53 and/or PIK3CA mutations. The detection of these multiple mutations appears to allow the identification of a subset of more aggressive tumors within the group and to bear information that should be useful for prognostic stratification of these patients including the planning of adjuvant therapy.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지